Literature DB >> 8317547

Immunohistochemical study of p53 in human lung carcinomas.

E Brambilla1, S Gazzeri, D Moro, C Caron de Fromentel, V Gouyer, M Jacrot, C Brambilla.   

Abstract

Immunohistochemical analysis of p53 protein was carried out on 95 lung carcinomas from all histological types, including 60 primary tumors, 35 lymph node metastases, and 36 corresponding nude mice xenografts, using four antibodies: PAb240 specific for some mutant conformations; PAb421, PAb1801, and CM1 reactive with most of the forms of p53. Nuclear staining with at least two of those four antibodies revealed the presence of an accumulated protein, considered as indicative of a missense mutation in the p53 gene, in 50% of primary tumors of all histological types, except carcinoids. Some defect of messenger RNA expression was detected by Northern blot analysis in an additional 26% of tumors. p53 immunophenotype of the original tumor was fairly maintained on nude mice. p53 accumulation was not correlated with survival, but with disease extension (P = 0.01). Finally, immunohistochemical analysis allowed the recognition of p53 mutant immunophenotype in 41% of tumors where p53 DNA and messenger RNA were apparently normal, using standard molecular biology. Thus, this method provides a rapid and efficient approach for studying p53 mutations leading to an accumulated protein in lung tumors cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8317547      PMCID: PMC1886967     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer.

Authors:  K Kok; J Osinga; B Carritt; M B Davis; A H van der Hout; A Y van der Veen; R M Landsvater; L F de Leij; H H Berendsen; P E Postmus
Journal:  Nature       Date:  1987 Dec 10-16       Impact factor: 49.962

3.  Localization of gene for human p53 tumour antigen to band 17p13.

Authors:  M Isobe; B S Emanuel; D Givol; M Oren; C M Croce
Journal:  Nature       Date:  1986 Mar 6-12       Impact factor: 49.962

Review 4.  A new international staging system for lung cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1986-04       Impact factor: 9.410

5.  Expression of the p53 protein during the cell cycle of human peripheral blood lymphocytes.

Authors:  W E Mercer; R Baserga
Journal:  Exp Cell Res       Date:  1985-09       Impact factor: 3.905

6.  p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells.

Authors:  V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

7.  p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors.

Authors:  A Rogel; M Popliker; C G Webb; M Oren
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

8.  Atypical endocrine tumors of the lung.

Authors:  E M McDowell; T S Wilson; B F Trump
Journal:  Arch Pathol Lab Med       Date:  1981-01       Impact factor: 5.534

9.  Radioimmunoassay of the cellular protein p53 in mouse and human cell lines.

Authors:  S Benchimol; D Pim; L Crawford
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

10.  The relationship of p53 immunostaining to survival in carcinoma of the lung.

Authors:  R McLaren; I Kuzu; M Dunnill; A Harris; D Lane; K C Gatter
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

View more
  18 in total

1.  Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival.

Authors:  Chun-Dong Gu; Toshihiro Osaki; Tsunehiro Oyama; Masaaki Inoue; Mantaro Kodate; Kazuhito Dobashi; Takeshi Oka; Kosei Yasumoto
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

2.  P53 expression in stage I squamous cell lung cancer.

Authors:  J Moldvay; J Strausz; M Egerváry; L Agócs; J Bocsi; Z Schaff
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

3.  Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours.

Authors:  N Kamio
Journal:  Virchows Arch       Date:  1996-05       Impact factor: 4.064

4.  Clinical importance of correlations between p53 immunoreactivity and clinicopathological parameters in lung carcinoma.

Authors:  B A Dursun; L Memiş; A Dursun; H Bayiz; M Ozkul
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

5.  Immunohistochemical detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18.

Authors:  M Akasofu; Y Oda
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma.

Authors:  H Kitamura; Y Kameda; N Nakamura; Y Nakatani; Y Inayama; M Iida; K Noda; N Ogawa; T Shibagaki; M Kanisawa
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

7.  Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.

Authors:  R M Przygodzki; S D Finkelstein; J C Langer; P A Swalsky; N Fishback; A Bakker; D G Guinee; M Koss; W D Travis
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

Review 8.  Clinical implication of p53 mutation in lung cancer.

Authors:  Barbara G Campling; Wafik S El-Deiry
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

9.  P53 accumulation and proliferating-cell nuclear antigen expression in human lung cancer.

Authors:  T Wiethege; B Voss; K M Müller
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers.

Authors:  M F Melhem; J C Law; L el-Ashmawy; J T Johnson; R J Landreneau; S Srivastava; T L Whiteside
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.